Loading stock data…
Bristol-Myers Squibb Company discovers (BMY)
$62.09+0.58 (+0.94%)
Market ClosedLast close Jul 24
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bristol-Myers Squibb Company in the Healthcare sector is trading at $62.09 with a market capitalization of $114.6B. Wall Street consensus targets $62.96 (24 analysts), implying a +1.4% move over the next 12 months. The stock is currently near its 52-week high of $62.89, remaining 14.9% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.49B↓ | $12.50B↑ | $12.22B↓ | $12.27B↑ | $11.20B |
| Gross Profit | $8.07B↓ | $8.41B↓ | $8.79B↓ | $8.90B↑ | $8.17B |
| Operating Income | $3.37B↑ | $2.81B↓ | $3.64B↓ | $3.77B↑ | $3.50B |
| Net Income | $2.68B↑ | $1.09B↓ | $2.20B↑ | $1.31B↓ | $2.46B |
Peer Comparison
JNJUNHPFE
Fundamentals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$114.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
4.03%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.25%
Volume
Today's trading volume
11.98M
Recent News
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer
Sometimes you need to look beyond the numbers to get the full story.
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $61.4, denoting a +1.05% move from the preceding trading day.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.